| Literature DB >> 32692445 |
Xunhao Xiong1,2, Geeta Rao1,2, Ram Vinod Roy1,2, Yushan Zhang1,2, Nicolas Means1,2, Anindya Dey1,2, Martha Tsaliki1,2, Sounik Saha1,2, Sanjib Bhattacharyya3, Shailendra Kumar Dhar Dwivedi1,2, Chinthalapally V Rao4, Daniel J McCormick3, Danny Dhanasekaran1,5, Kai Ding6, Elizabeth Gillies2, Min Zhang7, Da Yang7, Resham Bhattacharya1,8, Priyabrata Mukherjee1,2.
Abstract
Macropinocytosis supports the metabolic requirement of RAS-transformed pancreatic ductal adenocarcinoma cells (PDACs). However, regulators of RAS-transformation (activation) that lead to macropinocytosis have not been identified. Herein, we report that UBAP2 (ubiquitin-binding associated protein 2), regulates the activation of KRAS and macropinocytosis in pancreatic cancer. We demonstrate that UBAP2 is highly expressed in both pancreatic cancer cell lines and tumor tissues of PDAC patients. The expression of UBAP2 is associated with poor overall survival in several cancers, including PDAC. Silencing UBAP2 decreases the levels of activated KRAS, and inhibits macropinocytosis, and tumor growth in vivo. Using a UBAP2-deletion construct, we demonstrate that the UBA-domain of UBAP2 is critical for the regulation of macropinocytosis and maintaining the levels of activated KRAS. In addition, UBAP2 regulates RAS downstream signaling and helps maintain RAS in the GTP-bound form. However, the exact mechanism by which UBAP2 regulates KRAS activation is unknown and needs further investigation. Thus, UBAP2 may be exploited as a potential therapeutic target to inhibit macropinocytosis and tumor growth in activated KRAS-driven cancers.Entities:
Keywords: KRAS; UBAP2; macropinocytosis; pancreatic cancer; small GTPases; therapeutic target
Year: 2020 PMID: 32692445 PMCID: PMC7808438 DOI: 10.1096/fj.201902826RR
Source DB: PubMed Journal: FASEB J ISSN: 0892-6638 Impact factor: 5.191